Cartesian Therapeutics RNAC
NASDAQ RNAC
$9.27 +0.15 (+1.64%)
At close: Sep 4, 2026 · 4:00 PM EDT

Cartesian Therapeutics (RNAC) EBIT Margin Growth (3y) (2018 - 2026)

Analysis

Cartesian Therapeutics (RNAC) EBIT Margin Growth (3y) (2018 - 2026) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EBIT Margin Growth (3y) (Qtr)
1 Vertex Pharmaceuticals 138.47 Bn 130.62 Bn 2.84 Bn -377.00
2 Regeneron Pharmaceuticals 85.18 Bn 77.19 Bn 3.93 Bn -204.00
3 Argenx Se 63.38 Bn 58.19 Bn 1.37 Bn 7,045.00
4 Moderna 58.09 Bn 52.95 Bn 52.00 Mn -1,934.00
5 Revolution Medicines 44.33 Bn 44.33 Bn - -
6 BeOne Medicines 40.02 Bn 34.92 Bn 1.53 Bn 7,261.00
7 Alnylam Pharmaceuticals 35.57 Bn 32.27 Bn 992.69 Mn 9,003.00
8 Royalty Pharma 28.45 Bn 27.61 Bn - -2,649.00
9 Insmed 27.48 Bn 26.32 Bn 358.27 Mn 30,461.00
10 Cartesian Therapeutics 271.98 Mn 271.98 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Mar 31, 2026 -3.37 Mn
Dec 31, 2025 -825,343.00
Sep 30, 2025 -465,290.00
Jun 30, 2025 -735,442.00
Mar 31, 2025 -202,160.00
Dec 31, 2024 350,825.00
Sep 30, 2024 -453,328.00
Jun 30, 2024 3,883.00
Mar 31, 2024 -16,378.00
Dec 31, 2023 -37,345.00
Sep 30, 2023 9,617.00
Dec 31, 2022 13,832.00
Jun 30, 2022 12.49 Mn
Mar 31, 2022 11.86 Mn
Dec 31, 2021 161,927.00
Dec 31, 2020 11.33 Mn
Sep 30, 2020 5.10 Mn
Dec 31, 2019 28,413.00
Jun 30, 2019 -12.46 Mn
Mar 31, 2019 -11.82 Mn